Principal Securities’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Principal Securities’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-184	Closed	-$4.34K	–	2370
2025 Q3	$4.34K	Sell	184 -3	-2%	-$66	﹤0.01%	3013
2025 Q2	$3.83K	Sell	187 -1,132	-86%	-$22.8K	﹤0.01%	2943
2025 Q1	$29.8K	Hold	1,319	–	–	﹤0.01%	1991
2024 Q4	$29.8K	Sell	1,319 -1,017	-44%	-$24.4K	﹤0.01%	1986
2024 Q3	$57.5K	Buy	2,336 +166	+8%	+$4.05K	﹤0.01%	1624
2024 Q2	$50.2K	Buy	2,170 +6	+0.3%	+$140	﹤0.01%	1622
2024 Q1	$52.1K	Sell	2,164 -424	-16%	-$9.94K	﹤0.01%	1548
2023 Q4	$59.5K	Buy	+2,588	New	+$52K	﹤0.01%	1408

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Principal Securities's IDNA Position: Q4 2025 in Review

Principal Securities sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q4 2025, closing a stake of 184 shares — an estimated $4.34K sold.

Principal Securities first reported a position in IDNA in Q4 2023 and held it in 8 quarters. The position peaked at $59.5K in Q4 2023. 58 funds tracked by Wall St. Rank hold IDNA as of Q4 2025.

Principal Securities reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 184 iShares Genomics Immunology and Healthcare ETF shares in Q4 2025, an estimated $4.34K.
Principal Securities first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2023 and held it in 8 quarters.
Principal Securities's iShares Genomics Immunology and Healthcare ETF position peaked at $59.5K in Q4 2023.
58 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.